NCT06581159

Study of HS135 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

Phase 1b Double-Blind, Placebo-Controlled, MAD Study Assessing the Pharmacokinetics, Safety, Pharmacodynamics, and Efficacy of HS135 in Obese Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: 35Pharma Inc · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Study of HS135 for the Treatment of in Obese Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Detailed description

Phase 1b, Multicenter, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Assessing the Pharmacokinetics, Safety, Pharmacodynamics, and Efficacy of HS135 in Obese Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction

Conditions

• Heart Failure With Preserved Ejection Fraction
• Pulmonary Hypertension

Interventions

Type	Name	Description
BIOLOGICAL	HS135	Subcutaneous Injection
OTHER	Placebo	Subcutaneous Injection

Timeline

• Start date: 2025-01-23
• Primary completion: 2025-07-29
• Completion: 2025-07-29
• First posted: 2024-09-03
• Last updated: 2025-09-04

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study